Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $133M (up 9.0% year over year) with net income of $60M.
Q3 2026 key financials · XBRL
- Revenue
- $133M
- +9.0% YoY · +17.7% QoQ
- Net income
- $60M
- +49.3% YoY · +16.7% QoQ
- Operating margin
- 70.0%
- EPS (diluted)
- $0.36
- +44.0% YoY · +16.1% QoQ
Source: XBRL data from the IRONWOOD PHARMACEUTICALS INC (IRWD) Q3 2026 10-Q on SEC EDGAR. USD.
IRONWOOD PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $133.0M, up $11.0M YoY, driven by LINZESS U.S. net-profit share
- Operating margin 70.0% vs 61.8% YoY, with operating income $93.1M vs $75.5M
- Apraglutide R&D $25.2M, up from $17.8M, the largest pipeline expense
- Cash $86.4M; operating cash flow $130.8M, financing outflow $259.7M
- STARS-2 recruiting; regulatory filing for apraglutide planned in 2029, subject to results
Risk Factors
- No material risk-factor changes disclosed; Item 1A contains no substantive risk discussion
- Partner concentration: AbbVie accounted for $132.1 million of $132.7 million accounts receivable
- Regulatory and legal exposure: Ferring settlement requires remaining $5.0 million payment by December 31, 2026
- Liquidity risk: cash declined to $86.4 million while revolving debt remained $325.0 million
- Commercial concentration: LINZESS U.S. collaboration generated $344.2 million of nine-month revenue through AbbVie
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRONWOOD PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.